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Abstract 
Genome-wide association studies of case-control status have advanced the understanding of the 
genetic basis of psychiatric disorders. Further progress may be gained by increasing sample size 
but also by new analysis strategies that advance the exploitation of existing data, especially 
for clinically important quantitative phenotypes. The f unctionally- i nformed e fficient r egion- 
based test s trategy (FIERS) introduced herein uses prior knowledge on biological function and 
dependence of genotypes within a powerful statistical framework with improved sensitivity 
and specificity for detecting consistent genetic effects across studies. As proof of concept, 
FIERS was used for the first genome-wide single nucleotide polymorphism (SNP)-based inves- 
tigation on bipolar disorder (BD) that focuses on an important aspect of disease course, the 
functional outcome. FIERS identified a significantly associated locus on chromosome 15 (hg38: 
chr15:48965004 – 49464789 bp) with consistent effect strength between two independent stud- 
ies ( GAIN/TGen : European Americans, BOMA : Germans; n = 1592 BD patients in total). Protec- 
tive and risk haplotypes were found on the most strongly associated SNPs. They contain a CTCF 
binding site (rs586758); CTCF sites are known to regulate sets of genes within a chromatin 
domain. The rs586758 – rs2086256 – rs1904317 haplotype is located in the promoter flanking re- 
gion of the COPS2 gene, close to microRNA4716, and the EID1, SHC4, DTWD1 genes as plausible 
biological candidates. While implication with BD is novel, COPS2, EID1 , and SHC4 are known 
to be relevant for neuronal differentiation and function and DTWD1 for psychopharmacological 
side effects. The test strategy FIERS that enabled this discovery is equally applicable for tag 
SNPs and sequence data. 
© 2018 The Author(s). Published by Elsevier B.V. This is an open access article under the CC 
BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
1. Introduction 
For years, collaborative consortia have vastly increased 
sample sizes for genome-wide association studies (GWAS). 
However, worldwide sample size is finite, and data on clin- 
ically important quantitative phenotypes is currently lim- 
ited, largely due to high costs of deep phenotyping and 
lacking harmonization of assessment scales and conditions 
across studies. Nevertheless, quantitative phenotypes are 
especially valuable for understanding underlying biologi- 
cal mechanisms and between-patient heterogeneity. Hence, 
complementary to increasing sample size, new approaches 
and strategies that advance the exploitation of existing 
genome-wide data are highly desirable. 
To gain power and identify underlying mechanisms, re- 
cently single-marker tests have been replaced by joint 
statistics on biological units ( Subramanian et al., 2005; 
Wang et al., 2007 ). Joint statistics greatly reduce the 
multiple-testing burden and may increase power by ag- 
gregating association signals from multiple functionally- 
related loci. Many pioneering approaches have aggregated 
single-SNP GWAS p -values into enrichment statistics for 
genes or pathways ( Wang et al., 2010 ). However, unbiased 
scoring often necessitates time-consuming permutation 
procedures, since genes and pathways differ in numbers of 
SNPs, gene length, gene number and linkage disequilibrium 
(LD)-patterns. Alternatively, SNPs may be aggregated into 
polygenic risk scores that serve for association testing or 
trait prediction ( Dudbridge, 2013 ). Risk scores reduce the 
model space: they collapse multiple SNPs into a single score 
with a priori assumptions on the selection and weighting of 
contributing SNPs ( Dudbridge, 2013 ). A third set of meth- 
ods provide actual joint tests of SNPs at the individual- 
data level. Among them, the kernel score test SKAT ( Schaid, 
2010 ) is very powerful for a broad range of genetic ar- 
chitectures, computationally convenient, and yields exact 
p -values. 
Whereas LD is a nuisance for most statistics, SKAT can 
exploit LD to increase power compared to single-marker 
tests ( Schifano et al., 2012 ) to the extent that testing LD- 
blocks with SKAT is especially powerful ( Malzahn et al., 
2016 ). Since SKAT is a joint test, power increases with cu- 
mulative association strength and the ratio between sam- 
ple size and number of jointly tested SNPs. Therefore, tag 
SNPs may provide higher power than a denser common SNP 
panel of the same region ( Malzahn et al., 2014 ). Whereas 
association strengths and available sample sizes depend 
on studied phenotypes, sizes of tested SNP sets are the 
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analysts’ choice. Of all 284 human pathways listed in the 
KEGG ( Kanehisa and Goto, 2000 ) database at the time of 
download, only 9.5% contained fewer than 500 SNPs of a typ- 
ical GWAS marker panel, but 47% of the pathways contained 
more than 2000 SNPs, and the longest pathway contained 
around 14,500 SNPs. For clinically important phenotypes 
however, primary studies or even worldwide samples with 
comparable phenotyping may encompass only a few thou- 
sand subjects. In these instances, power likely differs pro- 
foundly between short and long pathways, whereas smaller 
biological units provide stable power. Note also that path- 
ways may share genes and genes may share SNPs, thus yield- 
ing partially overlapping test sets. Herein, we leverage the 
observed enrichment of small p -values across GWAS among 
SNPs linked with specific functional elements ( Schork et al., 
2013 ). We a priori identify and test only LD-blocks contain- 
ing specific functional SNPs, considering these regions pu- 
tatively relevant in a hypothesis-driven GWAS. A variety of 
classes of putative functionality of SNPs may be used for 
selecting genomic regions of interest a priori . Herein, we 
chose to use non-synonymous coding SNPs (nsSNPs) and no 
other functional information, as currently nsSNPs can be 
most reliably predicted ( Li and Wei, 2015; Saunders and 
Baker, 2002 ) and many genes implicated with BD suscep- 
tibility ( Hou et al., 2016 ), the disorder of interest herein, 
are protein coding. Hence the presented analysis focused on 
LD-blocks that overlap with protein-coding sections of the 
genome, with the extension that exploiting LD putatively 
may include additional information from SNPs with other 
functionalities as well. The testing of LD-blocks fully capi- 
talizes on SKAT’s advantages. In addition, we improved sen- 
sitivity and specificity to detect consistent genetic effects 
across studies by employing an extension of SKAT ( Malzahn 
et al., 2014 ) for cross-study analysis of individual-level data 
(mega-analysis). 
As proof of concept, we demonstrate the success of this 
f unctionally- i nformed e fficient r egion-based test s trategy 
(FIERS) to uncover genetic risk factors for functional out- 
come in bipolar disorder (BD) in two independent stud- 
ies, Genetic Information Association Network ( GAIN) ( Smith 
et al., 2009 )/ Translational Genomics Research Institute 
(TGen) study ( Smith et al., 2011 ), United States, and 
the Bonn-Mannheim (BOMA) study ( Cichon et al., 2011; 
Fangerau et al., 2005 ), Germany, comprising 1592 pa- 
tients. BD is among the 20 leading causes of disability 
worldwide ( Vos et al., 2012 ) and genetic factors con- 
tribute to BD susceptibility ( Bienvenu et al., 2011; Charney 
et al., 2017 ). However, functional outcome of BD is highly 
variable. While some patients with a mild course of BD 
experience hardly any restrictions in work or personal re- 
lationships between illness episodes, an estimated 30–60% 
suffer from substantial impairment up to the point of 
disability ( Sanchez-Moreno et al., 2009 ). Apart from se- 
vere socio-economic consequences, impaired functional 
outcome also implies a reduced perceived quality of life 
of patients ( Sum et al., 2015 ). Several socio-demographic, 
clinical and cognitive factors associate with impaired func- 
tional outcome in BD (for an overview see Gade et al., 2015; 
Reinares et al., 2013; Solé et al., 2018 ). The knowledge of 
these factors and of their interplay is critical for optimiz- 
ing individualized treatment ( Reinares et al., 2013 ). Along 
the same line, it is of utmost importance to gain deeper 
insights into the biological underpinnings of between- 
patient heterogeneity of functional outcome of BD. 
Heritability and familial clustering of reduced global 
( Savage et al., 2012; Vassos et al., 2008 ), social ( Schulze 
et al., 2006 ), and occupational ( Potash et al., 2007 ) func- 
tioning in families of patients with schizophrenia ( Savage 
et al., 2012; Vassos et al., 2008 ) or BD ( Potash et al., 
2007; Schulze et al., 2006 ) suggest genetic influences. Fur- 
thermore, Global Assessment of Functioning (GAF; DSM-IV 
Axis V) was lower in healthy carriers of neuropsychiatric 
copy-number-variants compared to non-carriers ( Stefansson 
et al., 2013 ). We present here the first genomic study of 
functional outcome of BD. While BD has an episodic char- 
acter, most patients experience longer times outside of 
severe acute manic or depressive episodes than within. Con- 
sequently, FIERS was employed to analyze GAF assessed 
during outpatient treatment, as important cross-diagnostic 
indicator of overall course and severity of psychiatric 
disorder. 
2. Experimental procedures 
2.1. Study participants 
Data were provided by the GAIN / TGen study, United States 
( Smith et al., 2009, 2011 ), and the BOMA study, Germany 
( Cichon et al., 2011; Fangerau et al., 2005 ). All partici- 
pants gave written informed consent prior to study partic- 
ipation. Study protocols were approved by the respective 
institutional review boards and in accordance with the 1964 
Declaration of Helsinki. For the BOMA sample, summary 
statistics can be accessed via the Psychiatric Genomic 
Consortium ( http://www.med.unc.edu/pgc/ ) and individ- 
ual data by contacting the Institute of Psychiatric Phenomics 
and Genomics, University Hospital, LMU Munich, Germany 
(Thomas G. Schulze). GAIN/TGen data can be obtained by 
contacting the Bipolar Genome Study (John R. Kelsoe). GAIN 
genotypes are also available at the database of Genotypes 
and Phenotypes (phs000017.v3.p1). 
From GAIN/TGen , we analyzed 1081 adults of European 
American ancestry diagnosed with BD according to DSM-IV 
criteria who had GAF scores. GAIN/TGen provided imputed 
genome-wide genotypes (see Smith et al., 2009 , 2011 for 
details). Patient age ranged from 17 to 77 years (mean ± sd: 
43 ± 12 years), duration of illness from 0.5 to 64 years 
(mean ± sd: 24 ± 13 years), and 34.9% ( n = 377) of par- 
ticipants were men. Diagnoses were obtained based on the 
Diagnostic Interview for Genetic Studies (DIGS) ( Nurnberger 
et al., 1994 ) and review of available family history and med- 
ical records through a best estimate procedure. 
BOMA participants had minimal illness duration of 6 
months and were recruited for the purpose of genetic stud- 
ies ( Fangerau et al., 2005 ) from consecutive hospital admis- 
sions at the Central Institute of Mental Health, Mannheim 
and the Department of Psychiatry, University of Bonn, Ger- 
many. Diagnoses were established by the German version of 
the Structured Clinical interview for DSM-IV-TR Axis I Disor- 
ders (Diagnostic and Statistical Manual of Mental Disorders, 
4th ed, text revision, SCID-I) ( First et al., 2002; Wittchen 
and Fydrich, 1997 ). We analyzed 511 adult inpatients with 
a lifetime-diagnosis of BD according to DSM-IV criteria 
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and available pre-admission GAF scores and genome-wide 
genotypes (Illumina: HumanHap550v3, Human610, Hu- 
man660w) (17). BOMA patient age was comparable to 
GAIN/TGen and ranged from 18 to 78 years (mean ± sd: 
46 ± 13 years), duration of illness was on average shorter 
(ranging from 0.5 to 61 years, mean ± sd: 17 ± 12 years), 
and the proportion of men was higher (45.0%, n = 230). 
2.2. Phenotype 
Functional outcome was assessed by the GAF score (DSM-IV 
Axis V, American Psychiatric Association, 2002 ); details on 
scale development are described elsewhere ( Endicott et al., 
1976; Luborsky, 1962 ). GAF rates the overall psychological, 
social and occupational functioning of a subject on a con- 
tinuum ranging from 1 to 100 ( Luborsky, 1962 ). Poorer func- 
tioning is indicated by lower GAF scores. 
We analyzed GAF in BD outpatients to target course of 
disorder outside acute illness episodes. GAF assessments 
were performed by board-certified psychiatrists or psychol- 
ogists or psychiatry/psychology trainees at advanced stages 
in their postgraduate education. In GAIN/TGen , GAF was an 
average rating over the past (last) month assessed by di- 
rect interview of outpatients. Observed scores ranged from 
5 to 100 with a median score of 61. In BOMA , the GAF score 
represents a pre-admission state right before the “current”
episode for which the patient received clinical treatment at 
the time of study interview. Observed GAF scores in BOMA 
were higher compared to GAIN/TGen and ranged from 25 to 
100 with a median score of 80. 
2.3. Statistical methods – FIERS 
FIERS applied a hypothesis-guided filter on the genome, 
combining two types of prior information: LD structure 
(from independent reference data) and functional knowl- 
edge (from bioinformatic annotation tools). The goal was 
to a priori identify LD-blocks that contain specific func- 
tional elements. In a second step, only these LD-blocks were 
tested for genotype-phenotype association by employing a 
generalization of SKAT ( Malzahn et al., 2014 ) for cross-study 
analysis of individual-level data (mega-analysis, details be- 
low). This comprised the genotypic information of an LD- 
block into a single association test, yielding a single p - 
value per LD-block, respectively. The employed generaliza- 
tion of SKAT was especially powerful since it methodically 
optimally exploited all available information; specifically, 
genomic correlations and consistency (or lack thereof) of 
putative genetic effects across samples. Finally, to gain ad- 
ditional insight, the detected significant LD-block was ex- 
amined in detail by single-SNP and haplotype association 
analyses. 
2.3.1. FIERS – step I: hypothesis-guided LD-based 
selection of genomic regions 
Prior information on nsSNPs and LD were obtained for in- 
dependent population-based reference data from the In- 
ternational Haplotype Map Project (HapMap phase II CEU 
sample – northern and western European ancestry; 2591820 
SNPs, Sabeti et al., 2003 ) and matched to GAIN/TGen and 
BOMA using hg38 SNP-positions obtained with biomaRt (bio- 
conductor). A listing of nsSNPs was obtained based on SNP 
rs-identifier numbers from SNPnexus ( Dayem Ullah et al., 
2013 ) as predicted by at least one of the widely accepted 
SIFT ( Kumar et al., 2009 ) or PolyPhen ( Adzhubei et al., 2010 ) 
bioinformatics tools ( Friedrichs et al., 2016 ), and irrespec- 
tive of predicted nsSNP impact as this may vary across tran- 
script isoforms. The hg38 start and end positions of LD- 
blocks that contain these functionally annotated SNPs were 
determined using the default algorithm of Haploview 4.2 
( Barrett et al., 2005 ) such that within assigned LD-blocks 
at least 70% of all SNP pairs had D’ estimates with lower 
95% confidence limits above 0.5. The rationale was to de- 
tect reasonably strongly correlated SNP sets for subsequent 
combined evaluation ( Malzahn et al., 2016 ). 
GAIN/TGen and BOMA samples were genetically homoge- 
neous and indistinguishable in the four most important prin- 
cipal components (multidimensional scaling analysis, PLINK, 
data not shown; see Table 1 and Fig. 2 [symbols in bottom 
panel] for high cross-study similarity of estimated variant 
frequencies and SNP correlations). Combining external LD 
information with nsSNP data identified 2957 LD-based blocks 
for association testing (containing 51,382 SNPs in total) from 
410,943 common SNPs available in GAIN/TGen and BOMA af- 
ter quality control. SNPs were directly typed ( BOMA : Hardy- 
Weinberg equilibrium p -value ≥ 10 −5 , call rate ≥ 95%) or 
came from a larger imputed panel ( GAIN/TGen , see Smith 
et al., 2009 , 2011 for details on genotyping, quality con- 
trol and imputation). By construction, GWAS marker panels 
are LD-pruned. Nevertheless, substantial amounts of LD re- 
main and test strategy FIERS exploits this. The two largest 
tested LD-based blocks contained 430 and 186 SNPs; all 
other blocks contained fewer than 79 SNPs. With regards to 
nsSNP content, 72% of the tested LD-based blocks contained 
a single nsSNP, 28% contained at least two, with a maximum 
of 26 nsSNPs in a block. 
2.3.2. FIERS – step II: region-based cross-study analysis 
of individual-level data 
PLINK and R (version 3.2.2) were used for statistical anal- 
yses. All p-values reported are two-sided. Genetic associa- 
tion screening was performed for the full sample ( quanti- 
tative GAF ). Additionally, subjects who had GAF values in 
the lowest versus highest sample quartile were compared 
( GAF extremes ). All analyses were adjusted for fixed ef- 
fects of sex and duration of illness ( Gade et al., 2015 ). Pu- 
tative functional LD-based blocks were tested with SKAT in 
each study ( GAIN/TGen, BOMA ) and in cross-study analyses 
(mega-analysis of individual-level data; quantitative GAF : 
linear model, adjusting for between-study differences of 
GAF values by a random effect ( Malzahn et al., 2014 ); GAF 
extremes : logistic model, adjusting for between-study dif- 
ferences of GAF values by the additional covariate study ). 
Mega-analysis of individual-level data within SKAT assumed 
common SNP effects across studies and a linear kernel on 
minor allele dosages (additive model) with beta -density 
SNP-weights Beta (MAF,0.5,0.5) that depend on the minor 
allele frequency (MAF) of SNPs. This choice of kernel and 
SNP-weights ensured robust power for detecting genetic 
main effects ( Malzahn et al., 2016 ). Mega-analysis increased 
the power ( sensitivity ) for detecting reproducible genetic 
effects as it combined concordant effects across stud- 
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Table 1 GAF in BD outpatients associates with an LD-block on chromosome 15 (hg38: chr15:48965004 – 49464789 bp). 
Position Frequency Effect on quantitative GAF Effect on GAF extremes 
REGION a Single studies Mega analysis Single studies Mega analysis 
Chromosome 15 48965004 – 44 SNPs GER P = 4.9 × 10 −4 P = 1.3 × 10 −5 GER P = 5.4 × 10 −4 P = 5.6 × 10 −6 
49464789 US P = 5.9 × 10 −3 US P = 1.6 × 10 −3 
Top-ranked SNPs within this region b and negatively correlated nsSNP rs11854184 
SNP MA Position Frequency Effect: beta b 95%CI b Meta-analysis Effect: OR b 95% CI b Meta-analysis 
rs4474633 A 48968404 GER 0.316 GER −3.72 [ −5.63, −1.80] P = 4.4 × 10 −5 GER 2.21 [1.47, 3.42] P = 1.3 × 10 −5 
US 0.329 US −1.59 [ −2.93, −0.25] US 1.48 [1.14, 1.93] 
rs11854184 A 49000997 GER 0.199 GER 2.84 [0.54, 5.13] P = 0.013 GER 0.56 [0.33, 0.91] P = 0.013 
US 0.188 US 1.34 [ −0.32, 3.00] US 0.75 [0.54, 1.03] 
rs2413930 T 49083018 GER 0.230 GER −4.12 [ −6.28, −1.97] P = 1.5 × 10 −5 GER 2.26 [1.44, 3.63] P = 5.8 × 10 −6 
US 0.285 US −1.99 [ −3.38, −0.61] US 1.63 [1.23, 2.16] 
rs586758 A 49216375 GER 0.287 GER −3.81 [ −5.80, −1.82] P = 2.5 × 10 −5 GER 2.31 [1.51, 3.62] P = 2.0 × 10 −6 
US 0.297 US −1.84 [ −3.21, −0.47] US 1.63 [1.23, 2.17] 
rs2086256 T 49265829 GER 0.346 GER −3.23 [ −5.13, −1.33] P = 1.1 × 10 −5 GER 2.06 [1.37, 3.16] P = 4.6 × 10 −6 
US 0.348 US −2.27 [ −3.60, −0.94] US 1.62 [1.24, 2.13] 
rs1904317 T 49270069 GER 0.289 GER −3.79 [ −5.77, −1.81] P = 2.5 × 10 −5 GER 2.28 [1.49, 3.56] P = 2.2 × 10 −6 
US 0.297 US −1.84 [ −3.22, −0.47] US 1.63 [1.23, 2.17] 
Six-locus haplotype c rs4474633 – rs11854184 – rs2413930 – rs586758 – rs2086256 – rs1904317 
Haplotype group Position Frequency Effect: beta c 95%CI c Single studies Effect: OR c 95% CI c Single studies 
∗∗∗GCC 48968404 – GER 0.654 GER 3.23 [1.33, 5.13] P = 9.1 × 10 −4 GER 0.49 [0.32, 0.73] P = 6.6 × 10 −4 
49270069 US 0.652 US 2.27 [0.94, 3.60] P = 8.3 × 10 −4 US 0.62 [0.47, 0.81] P = 4.4 × 10 −4 
∗∗∗ATT 48968404 – GER 0.287 GER −3.81 [ −5.80, −1.82] P = 2.0 × 10 −4 GER 2.31 [1.51, 3.62] P = 1.8 × 10 −4 
49270069 US 0.297 US −1.84 [ −3.22, −0.47] P = 8.7 × 10 −3 US 1.63 [1.23, 2.17] P = 6.7 × 10 −4 
∗∗∗GTC 48968404 – GER 0.058 GER 0.86 [ −2.99, 4.72] P = 0.661 GER 0.76 [0.29, 1.93] P = 0.567 
49270069 US 0.051 US −2.36 [ −5.14, 0.42] P = 0.097 US 1.16 [0.68, 1.97] P = 0.587 
CI, confidence interval; GER, German ( BOMA study); MA, minor allele; nsSNP, non-synonymous coding SNP; OR, odds ratio; P, p -value; US, US American Europeans ( GAIN/TGen study). 
a SKAT cross-study mega-analysis of individual-level BOMA and GAIN/TGen data on chromosome 15, hg38: chr15:48965004 – 49464789 bp ( quantitative GAF : linear model, GAF extremes : 
logistic model; adjusted for sex, illness duration, and study; see Methods for details). SKAT-derived p -values ( P ) summarize the joint influence of the available 44 SNPs in this LD-block on 
quantitative GAF and GAF extremes . 
b Displayed are single-SNP analyses of additive minor allele effects on functional outcome for the five most strongly associated SNPs and the enclosed nsSNP rs11854184 in the significant 
LD-block. Analyses within studies are adjusted for sex and illness duration. Studies were meta-analytically combined by Fisher’s p -value pooling. A protective minor allele effect is indicated 
by a positive regression coefficient beta > 0 ( quantitative GAF , linear model) and odds ratio OR < 1 (contrast between GAF extremes , logistic model); beta < 0, OR > 1 for risk minor alleles. 
Minor allele dosages of all five strongly associated SNPs are pairwise strongly positively correlated, and negatively correlated to the minor allele dosage of putative nsSNP rs11854184 . 
c Individual best-estimate haplotypes were nonambiguous on the last three positions and grouped accordingly. The three most frequent haplotype groups had the identifying nucleobase 
combinations GCC, ATT, GTC at rs586758, rs2086256, rs1904317; nucleotide base combinations at rs4474633, rs11854184, rs2413930 varied (indicated by ∗∗∗). For haplotype groups, an 
additive haplotype effect on functional outcome was tested in each study, with adjustment for sex and illness duration. Effects (beta, OR) are specified per haplotype copy. A protective 
haplotype effect is indicated by a positive regression coefficient beta > 0 ( quantitative GAF , linear model) and odds ratio OR < 1 ( GAF extremes , logistic model); beta < 0, OR > 1 for risk 
haplotypes. 
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Fig. 1 Mega-analysis of GAF in German and European American BD outpatients, adjusted for sex and duration of illness. 
Manhattan-like plots display SKAT-derived p -values on the 2957 tested putatively functionally relevant LD-based genomic 
regions (cross-study mega-analysis of individual-level BOMA and GAIN/TGen data). Significance (horizontal line, Bonferroni 
α = 0.05/2,957 = 1.7 × 10 −5 ) was reached for both quantitative GAF and GAF extremes for an LD-block on chromosome 15 
(hg38: chr15:48965004 – 49464789 bp). The dashed vertical line highlights the coinciding location of significance. 
ies into more powerful common effect estimates. Mega- 
analysis also increased specificity since discordant effect di- 
rections across studies will (partially) cancel into small(er) 
average effects, which suppresses their detection. SKAT 
exact p -values were obtained by Davies method ( Davies, 
1980 ). For the 2957 SKAT tests performed, the multiple- 
testing adjusted significance threshold was α = 1.7 × 10 −5 
(Bonferroni). 
2.3.3. FIERS – step III: detailed insight into significant 
regions 
For the 44 SNPs in the detected significant LD-block, single- 
SNP association tests were performed within studies and 
meta-analytically combined between studies by Fisher’s 
p -value pooling ( Fisher, 1925 ). Furthermore, individual best- 
estimate haplotypes on the five most strongly associated 
SNPs and an enclosed nsSNP were determined with PLINK. 
Haplotype association was analyzed within studies assum- 
ing an additive model of the effect of a haplotype or group 
of haplotypes, combining results meta-analytically across 
studies by Fisher’s p -value pooling. 
3. Results 
FIERS tested 2957 putatively relevant LD-based regions. 
Fig. 1 displays Manhattan-like plots of SKAT-derived 
p -values from cross-study mega-analysis of individual-level 
GAIN/TGen and BOMA data. SNP correlations within LD- 
based blocks were subsumed by SKAT tests. Hence SKAT 
tests of LD-based blocks are largely independent of one 
another. The traits quantitative GAF (all subjects) and 
GAF extremes (lowest versus highest study quartile) both 
identified the same significant LD-block on chromosome 15 
(hg38: chr15:48965004 – 49464789 bp; quantitative GAF 
p mega = 1.3 × 10 −5 , GAF extremes p mega = 5.6 × 10 −6 ). 
Of the 44 SNPs contained in this associated LD-block 
(see Supplement for summary statistics), 26 had consistent 
single-SNP effects across studies and meta-analysis p -values 
p meta < 0.05 for both traits (Fisher’s p -value pooling of stud- 
ies). Eighteen of these SNPs even had p -values p study < 0.05 
in both studies and traits ( Fig. 2 , top and middle panel). 
The five top-ranked SNPs ( p meta < 5 × 10 −5 , Table 1 ) 
have strongly positively correlated minor allele dosages 
( r > 0.67); rs586758 and rs1904317 are nearly synonymous 
( r = 0.998). In the vicinity lies a nsSNP (rs11854184); its mi- 
nor allele dosage is negatively correlated with that of the 
five top-ranked SNPs (range = −0.25 > r > −0.34). Individ- 
ual best-estimate haplotypes on these six SNPs (estimated 
with PLINK) were nonambiguous on the last three positions 
and grouped accordingly. This revealed a protective haplo- 
type group ( ∗∗∗GCC, quantitative GAF: p meta = 1.1 × 10 −5 , 
GAF extremes: p meta = 4.6 × 10 −6 ) and a risk haplotype 
group ( ∗∗∗ATT, quantitative GAF: p meta = 2.4 × 10 −5 , GAF 
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Fig. 2 Consistent effect strength across BD outpatient samples. 
In the associated LD-block hg38: chr15:48965004 – 49464789 bp, estimated minor allele effects were consistent across studies (US: 
GAIN/TGen , GER: BOMA ) for quantitative GAF (top, additive effect per minor allele) and GAF extremes (middle, multiplicative 
effect per minor allele; within-study single-SNP analyses, adjusted for sex and illness duration). Results are displayed for 18 SNPs 
that had p -values p study < 0.05 in each study and for nsSNP rs11854184 (square). Sign of effect estimates (risk: beta < 0, OR > 1; 
protective: beta > 0, OR < 1) corresponds to the correlation r of minor allele dosages (bottom panel, solid line) with CTCF binding 
site rs586758 (diamond). The latter is part of the discovered rs586758 – rs2086256 – rs1904317 haplotype (vertical lines, hg38: 
chr15:49216375 – 49270069 bp) and yielded the strongest association evidence among the 5 top-ranked SNPs ( p meta < 5 × 10 −5 , 
Table 1 middle panel). The 5 top-ranked SNPs have strongly positively correlated minor allele dosages ( r > 0.67 bottom panel, 
BOMA : filled symbols, GAIN/TGen : open symbols; square: nsSNP rs11854184). Lines ( D ’: dashed, r : solid) display the highly similar 
LD structure of a CEU reference population (1000 Genomes phase 3, northern and western European ancestry, obtained from 
Ensembl ( Cunningham et al., 2015 , http://www.ensembl.org/ ). 
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extremes: p meta = 2.0 × 10 −6 , Fisher’s p -value pooling of 
studies). Between-study consistency of haplotype associa- 
tion is displayed in Table 1 . A consistent reduction or in- 
crease of the risk of poor GAF, respectively, was also ob- 
served in all members of the two haplotype groups that 
were frequent enough for separate association testing (data 
not shown). 
4. Discussion 
Functional outcome in outpatient care is an important cross- 
diagnostic indicator for course of psychiatric disorder, clin- 
ically highly relevant, and highly variable in BD. To the 
best of our knowledge, this is the first SNP-based inves- 
tigation into the genetic basis of GAF in outpatient care. 
Despite moderate sample size, we identified a significant 
genomic region by introducing the efficient test strategy 
FIERS. Plausibility of our finding on chromosome 15 (hg38: 
chr15:48965004 – 49464789 bp) is supported by consistency 
of effect strength between independent BD patient samples 
( Fig. 2 ) and between genotyped ( BOMA ) and imputed SNPs 
( GAIN/TGen ). Moreover, further underlining plausibility, the 
association evidence centers at a functional SNP, and the as- 
sociated region overlaps with and lies in the vicinity of genes 
that are relevant for neuronal differentiation and function 
(see below). 
Single-SNP and haplotype analyses indicate that nsSNP 
rs11854184 is not likely responsible for the association. The 
reduced power of rs11854184 compared to the top-ranked 
SNPs ( Table 1 ) cannot sufficiently be explained by its lower 
minor allele frequency. In contrast, rs586758 displayed the 
strongest single-SNP association, was part of the discov- 
ered haplotypes (G/A position) and is a CTCF binding site 
( Cunningham et al., 2015 ). CTCF sites regulate groups of 
genes within a chromatin domain. 
GAF is not a measure of cognition and may deteriorate 
in psychiatric disorder for several reasons as it comprises 
social, occupational, and psychological functioning into a 
single score. Nevertheless, functional outcome and degree 
of cognitive impairment are significantly associated in BD 
and schizophrenia patients ( Bowie et al., 2010 ). Further- 
more, GAF scores and cognitive performance were lower in 
healthy carriers of neuropsychiatric copy-number-variants 
compared to non-carriers ( Stefansson et al., 2013 ). The 
novel associated haplotype reported herein is located in the 
promoter flanking region of the COPS2 gene (COP9 signalo- 
some subunit 2, also known as TRIP15, CSN2, ALIEN ), near 
microRNA4716 as plausible biological candidates. COPS2 is 
involved in cell cycle regulation and DNA repair, mediates 
gene silencing, and participates in modulating hormone re- 
sponse and cell proliferation ( Papaioannou, 2007 ). More- 
over, functional studies demonstrated that COPS2 plays cru- 
cial roles in neuronal differentiation and development as 
well as in maintaining neuronal functions ( Akiyama et al., 
2003; Chaerkady et al., 2011 ). Adjacent to the significantly 
associated LD-block, three additional genes are of inter- 
est: upstream EID1 (EP300 interacting inhibitor of differen- 
tiation 1) which influences synaptic plasticity and memory 
function ( Liu et al., 2012 ) and SHC4 (Src homology 2 domain 
containing family member 4, also known as ShcD ) which 
contributes to the regulation of neuronal function through 
mediation of the tyrosine kinase receptor TrkB downstream 
signaling pathway ( You et al., 2010 ). Downstream, gene 
DTWD1 (DTW domain containing 1) has previously been im- 
plicated in a pharmacogenomics study on side-effects of 
antidepressant treatment ( Clark et al., 2012 ). Hence it is 
conceivable that DTWD1 regulation through CTCF binding 
at rs586758 might alter GAF by altering side-effects of 
psychopharmacological medication and hence medication 
adherence. 
A particular strength of this study is the test strategy. 
FIERS contributes to more powerful analyses of existing 
genome-wide data in general and even enables successful 
genomic analyses of moderately sized samples. Using gen- 
eral prior knowledge on putative function and LD, FIERS 
better focused association screening on relevant parts of 
the genome which greatly reduced the number of statisti- 
cal tests performed. Across GWAS, small p -values are espe- 
cially enriched among SNPs that are in LD with specific func- 
tional elements ( Schork et al., 2013 ). FIERS exploits this by 
jointly testing SNPs within LD-based regions opposed to only 
testing functionally annotated SNPs. Among the variety of 
functional annotations that may be used to select LD-blocks 
a priori, nsSNPs have been most extensively validated so 
far . Currently, SIFT and PolyPhen provide one of the most 
widely accepted and accurate ( Saunders and Baker, 2002 ) 
annotations (nsSNPs) whereas it is still difficult to annotate 
and predict non-coding SNPs ( Li and Wei, 2015 ). Analyzing 
nsSNP-containing LD-blocks focused this analysis on protein- 
coding regions of the genome with the extension that ex- 
ploiting LD putatively included additional information from 
SNPs with other functionalities as well. 
A further strength of this investigation is cross-study 
mega-analysis, i.e. joint analysis of individual-level data 
across studies within SKAT. With appropriate covariate- 
adjustments, mega-analysis uses the data most efficiently 
and yields the greatest power. Mega-analysis within SKAT as- 
sumed concordant SNP effects across studies. This increased 
sensitivity for detecting replicable genetic effects and in- 
creased specificity by suppressing detection of discordant 
effects. In comparison, meta-analysis by Fisher’s p -value 
pooling of separately analyzed covariate-adjusted studies 
was less sensitive and less specific but confirmed the re- 
ported significance on chromosome 15, albeit with lower 
power (data not shown). If mega-analysis should become 
infeasible (e.g., because studies have different covariates 
to accommodate or individual-level data cannot be shared), 
SKAT score statistics may also meta-analytically, i.e. on the 
level of summary statistics, account for between-study con- 
cordance of SNP effects ( Lee et al., 2013 ). 
Mandatory for power of any statistical method is that 
size of the unit of analysis (LD-block, gene, pathway) and 
model complexity (main effects, genetic interactions) are 
appropriate in relation to available sample size. Although 
large from a clinical perspective, available sample size was 
a study limitation. We mastered this challenge by testing 
putatively functionally relevant LD-blocks for main effects. 
For larger samples, natural extensions are analyzing genes 
or pathways and allowing for genetic interactions ( Liu et al., 
2007 ). In general, summary statistics on biological units ei- 
ther use select representative SNPs ( Li et al., 2011 , 2012 ) 
or aggregate association evidence from all contained SNPs. 
Aggregation is easily, exactly, and powerfully accomplished 
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by SKAT on individual-level data. In contrast, tedious cor- 
rections for SNP correlations are required when aggregat- 
ing single-SNP p -values, e.g. by Fisher combination test ( de 
Leeuw et al., 2016; Li et al., 2011 ). Other p -value based 
joint tests such as count-based (SNP-ratio or hypergeomet- 
ric test) and rank-based (Kolmogorov–Smirnov) enrichment 
statistics suffer similar drawbacks as the Fisher combination 
test but with lower power ( de Leeuw et al., 2016 ). Using 
representative SNPs instead of fully aggregating all evidence 
is more powerful only when causal SNPs are greatly outnum- 
bered within tested SNP sets ( Li et al., 2011 ) or when causal 
SNPs cannot share association signals well with other SNPs, 
e.g., due to low minor allele frequency ( Li et al., 2012 ). 
Analogously, single-SNP tests may be more powerful than 
aggregate tests if associations are strong but involve very 
few SNPs only ( Chen et al., 2014 ). Otherwise, SKAT is very 
often among the most powerful methods, and is robustly 
powerful for a broad range of genetic architectures (see be- 
low) ( Chen et al., 2014; Li et al., 2012 ). Since SKAT tests 
combine individual-level information of multiple SNPs and 
their correlations, they exploit most of the information used 
in genotype imputation – without doing imputation ( Howey 
and Cordell, 2014 ). SKAT can also analyze sequence and rare 
variants ( Malzahn et al., 2016; Wu et al., 2011 ). However, LD 
should always be estimated on sufficiently frequent SNPs to 
avoid premature division of LD-blocks. As a self-contained 
test ( de Leeuw et al., 2016 ), SKAT evaluates whether any of 
the jointly tested SNPs associates with a trait of interest. 
Aggregation of associations (multiple loci, pathway effects) 
but also relatively localized yet sufficiently strong associa- 
tions such as polygenes or minor genes within pathways may 
make SKAT significant. This consideration hardly makes a 
difference for the LD-block analyses presented herein. How- 
ever, it highlights that for correct data interpretation, ge- 
netic architectures underlying SKAT significances should be 
examined. 
So far, the success of psychiatric genetics is largely based 
on the strategy of founding large consortia for case-control 
studies. However, data on clinically important quantita- 
tive phenotypes is still limited, largely due to high costs 
of deep phenotyping and lacking harmonization of assess- 
ment scales and conditions across studies. Owing to this, 
a potential limitation of the present investigation is that 
only two independent studies were available. That signif- 
icance was reached in the total sample but not in single 
studies is typical for GWAS which commonly regard con- 
sistency of effect estimates across studies ( Fig. 2 ) as ad- 
ditional conclusive evidence. Nevertheless, our consistent 
finding that rs586758 – rs2086256 – rs1904317 haplotype ATT 
carriers ( BOMA : 49.2% ± 4.3%, GAIN/TGen : 50.6% ± 3.0%) 
have lower GAF values would require additional indepen- 
dent validation. Furthermore, no information on medica- 
tion or medication adherence was available and GAF as- 
sessment differed to some extent between studies. GAF 
was assessed at a time point ( BOMA : pre-admission), or 
averaged over a period ( GAIN / TGen : past month) during 
which the state of illness, although sufficiently remitted 
for outpatient care, may have varied. Statistical analyses 
were adjusted for between-study differences of GAF values. 
Nevertheless, differences of GAF assessment might yield 
phenotypes with slightly different underlying biological 
mechanisms. This may explain why genetic effects in the as- 
sociated region ( Table 1 and Fig. 2 ), while consistent across 
studies, were slightly stronger in the putatively better re- 
mitted BOMA sample compared to GAIN / TGen . 
GAF is an overall rating of a patient’s psychological, social 
and occupational functioning. While clinically highly rele- 
vant and commonly used, a single overall score also presents 
some limitations. Specifically, GAF scores lack information 
regarding which of the three domains was most impaired 
and most decisive for individual overall rating. For exam- 
ple, a suicidal person with well-functioning relationships 
and good performance at his or her job would be assigned 
a very low GAF score. Hence future research may proceed 
by operationalizing functional outcome with a more differ- 
entiated measure like e.g. the functioning assessment short 
test (FAST; Rosa et al., 2007 ). Furthermore, when analyz- 
ing GAF scores, it would be of interest to stratify or adjust 
analyses with respect to concomitant symptom severity. Un- 
fortunately, we did not have sufficient data for this, which 
is a study limitation. 
While low GAF scores may occur in psychiatric patients 
for clinically different reasons, the generality of the GAF 
can also be seen as an advantage: GAF is applicable across 
different psychiatric diagnoses that share a common poly- 
genic background ( Cross-Disorder Group of the Psychiatric 
Genomics Consortium, 2013; Forstner et al., 2017; Purcell 
et al., 2009 ) and could be an indicator of a more general 
resilience/ vulnerability factor. Hence it would be of great 
interest to analyze GAF or other measures of functional out- 
come also in other psychiatric disorders, such as schizophre- 
nia, and jointly in patients with different psychiatric 
disorders. 
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